Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma

Bibliography

• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Cancer Netw 2011;9:1020-58
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl 6):vi 55-8
   Google Scholar
• Brusamolino E, Bacigalupo A, Barosi G, et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009;94:550-65
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-27
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71
   PubMed Web of Science ®Google Scholar
• Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999;10:527-32
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6
   PubMed Web of Science ®Google Scholar
• Eghbali H, Raemaekers J, Carde P; The EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol 2005;66:135-40
   Google Scholar
• Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol 1979;2:101-5
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14
   PubMed Web of Science ®Google Scholar
• Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997;8:143-8
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:71-6
   PubMed Web of Science ®Google Scholar
• Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-64
   PubMed Web of Science ®Google Scholar
• Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD. Ann Oncol 2005;16:124-31
   PubMed Web of Science ®Google Scholar
• Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11
   PubMed Web of Science ®Google Scholar
• Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005;23:9208-18
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-8
   PubMed Web of Science ®Google Scholar
• Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198-207
   PubMed Web of Science ®Google Scholar
• Chisesi T, Bellei M, Luminari S. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011;29(32):4227-33
   PubMed Web of Science ®Google Scholar
• Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400-8
   PubMed Web of Science ®Google Scholar
• Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 2008;6(4):278-81
   PubMedGoogle Scholar
• Sureda A, Schouten HC. HPCT for Hodgkin's lymphoma in adults. Chapter 19.9. The EBMT-ESH handbook. In: Apperley J, Carreras E, Gluckman E, Masszi T, editors, The 2012 revised edition of the EBMT-ESH handbook on haemopoietic stem cell transplantation. 6th edition; 2012. p. 431-43
   Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease. Results of a BNLI randomized trial. Lancet 1993;341:1051-4
   PubMed Web of Science ®Google Scholar
• Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9:1871-9
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 1993;81:1137-45
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395-404
   PubMed Web of Science ®Google Scholar
• Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20:451-8
   PubMed Web of Science ®Google Scholar
• Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology 2009;497-506. doi:10.1182/asheducation-2009.1.497
   PubMedGoogle Scholar
• Carella AM. Role of hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2012;4(1):e2012059
   PubMedGoogle Scholar
• Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28:5074-80
   PubMed Web of Science ®Google Scholar
• Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814-22
   PubMed Web of Science ®Google Scholar
• Andre M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. J Clin Oncol 1999;17:222-9
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999;17:3101-9
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Rowlings PA, Zhang M-J, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood And Marrow Transplant Registry. J Clin Oncol 1999;17:534-45
   PubMed Web of Science ®Google Scholar
• Constans M, Sureda A, Terol MJ, et al. GEL/TAMO Cooperative Group. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol 2003;14:745-51
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467-75
   PubMed Web of Science ®Google Scholar
• Shafey M, Duan Q, Russell J, et al. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2012;53:596-602
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-52
   PubMed Web of Science ®Google Scholar
• Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989-94
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-6
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-30
   PubMed Web of Science ®Google Scholar
• Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113:161-71
   PubMed Web of Science ®Google Scholar
• Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993;11:704-11
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996;78:1293-9
   PubMed Web of Science ®Google Scholar
• Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995;6:543-9
   PubMed Web of Science ®Google Scholar
• Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991;77:2292-8
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002;13:1370-7
   PubMed Web of Science ®Google Scholar
• Reece DE, Barnett MJ, Shepherd JD, et al. High dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995;86:451-6
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280-6
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117:4208-17
   PubMed Web of Science ®Google Scholar
• Minn AY, Riedel E, Halpern J, et al. Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. Br J Haematol 2012;159:329-39
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone-marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-8
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588-95
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5
   PubMed Web of Science ®Google Scholar
• Van Besien K, Tabocoff J, Rodriguez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen related toxicity. Bone Marrow Transplant 1995;15:549-55
   PubMed Web of Science ®Google Scholar
• Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989;73:340-4
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Escalon MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007;40:505-13
   PubMed Web of Science ®Google Scholar
• Weaver CH, Petersen FB, Appelbaum FR, et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994;12:2559-66
   PubMed Web of Science ®Google Scholar
• Salar A, Sierra J, Gandarillas M, et al. GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001;27:405-12
   PubMed Web of Science ®Google Scholar
• Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008;87:43-8
   PubMed Web of Science ®Google Scholar
• Reece DE, Nevill TJ, Sayegh A, et al. Regimen related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999;23:1131-8
   PubMed Web of Science ®Google Scholar
• Seiden MV, Elias A, Ayash L, et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimen. Bone Marrow Transplant 1992;10:57-63
   PubMed Web of Science ®Google Scholar
• Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000;6:387-94
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000;25:309-13
   PubMed Web of Science ®Google Scholar
• Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997;3:261-6
   PubMedGoogle Scholar
• Musso M, Scalone R, Marcacci G, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010;45:1147-53
   PubMed Web of Science ®Google Scholar
• Hayes MT, Bartley J, Parsons PG, et al. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry 1997;36:10646-54
   PubMed Web of Science ®Google Scholar
• De Rossi A, Rossi L, Laudisi A, et al. Focus on fotemustine. J Exp Clin Cancer Res 2006;25:461-8
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118:3419-25
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26(27):4473-9
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204-10
   PubMed Web of Science ®Google Scholar
• Nieto Y, Popat U, Anderlini P, et al. Autologous stem-cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013;19(3):410-7
   PubMed Web of Science ®Google Scholar
• Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007;109:2481-9
   PubMed Web of Science ®Google Scholar
• Moskowitz A, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934-7
   PubMed Web of Science ®Google Scholar
• Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1646-52
   PubMed Web of Science ®Google Scholar
• Arai S, Letsinger R, Wong RM, et al. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2010;16:1145-54
   PubMed Web of Science ®Google Scholar
• Ramzi M, Mohamadian M, Vojdani R, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant 2012;10:163-7
   PubMed Web of Science ®Google Scholar
• Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996;14:572-8
   PubMed Web of Science ®Google Scholar
• Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996;14:1291-6
   PubMed Web of Science ®Google Scholar
• Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle Experience. J Clin Oncol 1993;11:2342-50
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's disease. J Clin Oncol 2001;19:4314-21
   PubMed Web of Science ®Google Scholar
• Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009;114:2060-7
   PubMed Web of Science ®Google Scholar
• Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011;29:971-8
   PubMed Web of Science ®Google Scholar
• Sureda A, Pereira MI, Dreger P; on behalf of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma. Curr Opin Oncol 2012;24:727-32
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007;21:2316-23
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1279-87
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus lymphoma effect after reduced intensity allogeneic transplantation. Lancet 2005;365:1934-41
   PubMed Web of Science ®Google Scholar
• Alvarez I, Sureda A, Caballero D, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin's lymphoma: results of a Spanish Prospective Cooperative Protocol. Biol Blood Marrow Transplant 2006;12:172-83
   PubMed Web of Science ®Google Scholar
• Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230-8
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Fludarabine melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257-64
   PubMed Web of Science ®Google Scholar
• Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-62
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldolero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47:906-23
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005;35:943-51
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-17
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008;41:765-70
   PubMed Web of Science ®Google Scholar
• Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin's lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010;115:3671-7
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin Lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009;145:369-72
   PubMed Web of Science ®Google Scholar
• Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurrent lymphomas. Blood 2007;109:486-91
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30(18):2183-9
   PubMed Web of Science ®Google Scholar
• Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre. Haematologica 2012;
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-203
   PubMed Web of Science ®Google Scholar
• Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008;45:118-25
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT01100502A: Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
   Google Scholar